テンペスト・セラピューティクス
Tempest Therapeutics, Inc.
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.34 | $0 | -$3M |
| 2026 Q1 | -2.53 | $0 | -$8M |
| 2025 Q4 | -0.82 | $0 | -$4M |
| 2025 Q3 | -0.79 | $0 | -$7M |
| 2025 Q2 | -2.07 | $0 | -$8M |
| 2025 Q1 | -3.16 | $0 | -$8M |
| 2024 Q4 |
| -0.50 |
| $0 |
| -$10M |
| 2024 Q3 | -0.41 | $0 | -$10M |